Dactolisib

Dactolisib (also known as BEZ235) is an experimental drug candidate for the treatment of various types of cancer. It is a dual PI3K inhibitor and mTOR inhibitor and has been shown to inhibit both phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) in preclinical studies.

Mechanism of Action[edit | edit source]

Dactolisib works by inhibiting the PI3K/AKT/mTOR pathway, which is often overactive in many types of cancer. This pathway is involved in cell growth, proliferation, and survival. By inhibiting this pathway, Dactolisib can potentially slow down or stop the growth of cancer cells.

Clinical Trials[edit | edit source]

Dactolisib has been tested in several clinical trials for various types of cancer, including breast cancer, lung cancer, and renal cell carcinoma. However, the results have been mixed, and further research is needed to determine the effectiveness and safety of this drug.

Side Effects[edit | edit source]

Like all drugs, Dactolisib can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include hyperglycemia, pneumonitis, and rash.

Future Research[edit | edit source]

While Dactolisib has shown promise in preclinical studies and early-phase clinical trials, more research is needed to determine its effectiveness and safety in larger populations of patients. Future research may also explore the potential of Dactolisib in combination with other cancer treatments.

See Also[edit | edit source]

Dactolisib Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.